Sponsored by

Poster Number Index
Click on one of the following number ranges below to display a list of posters.
Click the checkbox next to each item to bookmark.

101 – 200 | 201 – 300 | 301 – 400 | 401 – 500 | 501 – 600 | 601 – 700 | 701 – 800
801 – 900 | 901 – 1000 | 1001 – 1100 | 1101 – 1200 | 2001 – 2100 | 2101 – 2200 | 3001 – 3100
3101 – 3200 | 4001 – 4100 | 4101 – 4200 | 5001 – 5100 | 5101 – 5200 | 6001 – 6100 | 6101 – 6152

  [1001] Allergic reactions to patent blue dye V – the ALMANAC and NEW START experience (on behalf of the ALMANAC study group).
  [1002] Quantitative intra-operative RT-PCR assay predicts size of sentinel node metastases.
  [1003] Intraoperative molecular sentinel lymph node analysis with OSNA: multicentre prospective UK evaluation.
  [1004] Intra-operative sentinel lymph node metastasis detection by “one-step nucleic acid amplification (OSNA)”: results of the french multicentric study.
  [1005] Assessment of the performance of the Stanford online calculator for the prediction of non-sentinel lymph node metastasis in sentinel node positive breast cancer patients.
  [1006] Technical aspects of the sentinel node biopsy in the EORTC AMAROS sentinel node trial.
  [1007] Value of axillary ultrasound and cytology in assessing nodal status preoperatively.
  [1008] Intra-operative touch imprint cytology for assessing sentinel lymph nodes in patients with lobular breast cancer.
  [1009] The significance of intramammary lymph node metastases in breast cancer management.
  [1011] Optimal detection of micrometastases in sentinel lymph node of breast cancer: CBCSG-001 trial.
  [1012] Selective axillary node dissection differed from the arm lymph flow oriented by 3D-CT lymphography.
  [1013] Non-image guided fine needle aspiration of palpable axillary lymph nodes in breast cancer patients.
  [1014] Cost utility analysis on one-step nucleic acid amplification method for the detection of axillary metastasis in breast cancer.
  [1015] Prognostic significance of sentinel nodes metastases in breast cancer patients without axillary node dissection or axillary radiotherapy: CBCSG-001 trial.
  [1016] Intraoperative training on the techniques of sentinel node biopsy in breast cancer.
  [1017] Five year follow-up of patients with operable breast cancer whose sentinel nodes were completely sectioned at 0.25mm.
  [1018] The use of touch prep for the evaluation of sentinel lymph nodes in breast cancer.
  [1019] The use of ultrasound in pre-operative assessment of the axilla in breast cancer.
  [1021] A new hand-held gamma camera for sentinel node detection in breast cancer. The Minicam experience in 50 cases.
  [1022] Subareolar injection may not always identify the same sentinel lymph nodes as peritumoral injection in breast cancer.
  [1023] The value of preoperative axillary ultrasound staging in the management of early breast cancer.
  [1024] The anatomically correct incidence of internal mammary node drainage on lymphoscintigraphy.
  [1025] Correlation between pN0(mol+) and standard clinico-pathological prognostic factors in SLN of breast cancer patients.
  [1026] Sentinel lymph node detection in breast cancer patients by real-time virtual sonography constructed with three-dimensional computed tomography-lymphography.
  [1027] Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVADO phase III study.
  [1028] VEGF, VEGFR2 and HIF-1α expression in circulating tumor cells (CTCs) of breast cancer patients.
  [1029] Angiogenic escape and tumour progression in two patients with metastatic breast cancer receiving bevacizumab treatment.
  [1030] Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with docetaxel (D) plus bevacizumab (BV) or placebo (PL) in the AVADO phase III study.
  [1033] Anti-angiogenic effects of tamoxifen in breast cancer by decreased secretion and reduced nuclear accumulation of angiogenin.
  [1034] Selective inhibition of VEGFR2 activity with a human anti-VEGF monoclonal antibody decreases tumor growth and macrophage infiltration in an orthotopic model of breast cancer.
  [1035] Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) ± bevacizumab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC).
  [1036] The effect of tetrathiomolybdate on circulating endothelial progenitor cells in patients with breast cancer at high risk of recurrence.
  [1037] Angiogenesis in breast cancer: comparison between three vascular endothelial markers.
  [1039] Effect of chronic exposure to tyrosine kinase inhibitors on chemotherapy-induced DNA damage in the SKBR3 breast cancer cell line.
  [1040] Identification of BRCA1 and BRCA2 genetic modifiers.
  [1044] Differences in outcome of young breast cancer patients according to BRCA1 mutation status.
  [1045] Lobular breast carcinoma as a possible candidate phenotype for recessively inherited breast cancer.
  [1047] TP53 mutation is an early event in breast cancer progression.
  [1049] Common wound healing signature in murine and human involuting breast, implications for pregnancy-associated breast cancer.
  [1050] Breast cancer instructs dendritic cells to express OX40 ligand and to prime pro-inflammatory type 2 CD4+ T cells that facilitate tumor development.
  [1051] Novel inflammatory breast cancer cell line, MDA-IBC-1 expresses and secretes WISP3, a putative tumor suppressor in inflammatory breast cancer.
  [1052] Potential promotion of metastatis of circulating breast cancer cells through interactions with mesenchymal stem cells (MSCs).
  [1054] Monocytes/macrophages and natural killer cells characterize the tumor microenvironment of inflammatory breast cancer in Egyptian patients.
  [1057] The microvasculature of invasive ductal breast carcinoma: a sterological approach.
  [1059] Fingerprinting genomic heterogeneity in primary breast carcinomas and among sentinel lymph node metastases: implications for clinical management of breast cancer patients.
  [1060] Brain metastases (BM) in patients presenting with HER-2 amplified advanced breast cancer (ABC).
  [1062] Immunohistochemistry-based marker profile accurately predicts risk in operable, hormone receptor-positive patients.
  [1063] The 70-gene prognosis profile predicts early metastases in postmenopausal breast cancer patients.
  [1064] DNA repair protein biomarkers in triple negative breast cancer.
  [1065] Effects of letrozole and anastrozole on low ER expressing invasive breast carcinomas: results from a randomised trial.
  [1066] A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy.
  [1067] P53 functional assay in yeast: evaluation in 1856 patients in a large prospective clinical trial (EORTC 10994/BIG 00-01).
  [1068] Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study.
  [1069] Combination of low plasma stromal cell-derived factor-1 and phosphorylated-CXCR4: independent prognostic marker for breast cancer.
  [1070] Local versus central HER2 immunohistochemistry correlates with kinetic RT-PCR but only central immunohistochemistry and RT-PCR predict pathological complete response: results from the neoadjuvant multicenter GeparTrio trial.
  [1071] Molecular breast cancer prognosis in node negative early breast cancer.
  [1072] Comparison of risk stratification by OncotypeDX versus HOXB13/IL17BR index and molecular grade index in 166 estrogen receptor positive patients from multiple institutions.
  [1073] Risk assessment of relapse in Swiss participants of BIG 1-98 with grade 2 early breast cancer by gene expression profiling using RNA from formalin-fixed, paraffin embedded (FFPE) tissue.
  [1075] Invasive breast carcinoma of 1 cm or smaller: risk of nodal involvement and prognosis.
  [1076] Is the prognostic value of Ki-67 dependent on ER status and histological grade?
  [1078] Breast cancer molecular subtypes and the risk of second malignancies.
  [1079] Amplification involving the CEP17 region may lead to false negative results of HER2 gene amplification by FISH.
  [1080] Improving NPI for breast cancer prognosis by including PR and HER-2 expression: own data and external validation set.
  [1081] Identification of three-genomic regions prognostic signature in small node-negative breast carcinomas.
  [1082] Expression of fatty acid synthase as a prognostic marker in triple negative breast cancer.
  [1083] Triple negative phenotype: not affecting survival in young patients with operable breast cancer.
  [1084] Benefit of the 70-gene profile for widely used guidelines: an answer to increased selection for adjuvant chemotherapy in breast cancer.
  [1085] Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple-negativity.
  [1086] Ki-67 gives additional prognostic information on St Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.
  [1087] Vascular endothelial growth factor receptor 2 is a significant negative prognostic biomarker in triple-negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer.
  [1089] HER2 status determined on pre operative biopsies and in operative specimens: concordance among immunohistochemistry (IHC) fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) techniques in the CRITHER study.
  [1090] Meningeal carcinomatosis in patients with breast cancer: clinical features and prognostic factors in 91 patients from a single institution.
  [1091] Focal adhesion kinase overexpression in breast cancer molecular subtypes.
  [1092] Determination of ASCO recommended prognostic factors uPA and PAI-1 in daily clinical routine and the node-negative NNBC 3-Europe trial.
  [1093] Breast cancer risk in mutation-negative members of known BRCA1/2 mutation-positive families.
  [1095] Factors affecting surgical decision-making in patients undergoing BRCA1/2 testing at breast cancer diagnosis.
  [1096] Self-administered, web-based screening of family history of cancer as a method to select appropriate patients for genetic assessment.
  [1097] The importance of updating the family history of breast cancer survivors.
  [1098] Telephone disclosure of BRCA1/2 test results: a survey of genetic counselors.
  [1099] Genetic counseling for BRCA1 and BRCA2 mutations in African American women.
  [1100] Assessing personal and family history characteristics of patients seeking cancer risk assessment due to direct-to-consumer marketing in a high risk clinic.

 
 

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved